Skip to main content

Advertisement

Advertisement

Advertisement

Advertisement

ADVERTISEMENT

Diffuse Large B-Cell Lymphoma (ASCO) Basic Listing

Updates in Diffuse Large B-Cell Lymphoma
From the ASCO Annual Meeting

Matthew Matasar, MD
Conference Coverage
06/11/2024

Featuring Matthew Matasar, MD

Featuring Matthew Matasar, MD
Matthew Matasar, MD, discusses ongoing data from the phase 3 OLYMPIA-3 trial which examines odronextamab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) versus rituximab plus CHOP among patients with previously...
Matthew Matasar, MD, discusses ongoing data from the phase 3 OLYMPIA-3 trial which examines odronextamab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) versus rituximab plus CHOP among patients with previously...
Matthew Matasar, MD, discusses...
06/11/2024
Oncology
John Burke, MD
Videos
06/04/2024

Featuring John Burke, MD

Featuring John Burke, MD
John Burke, MD, discusses some of the most compelling topics in diffuse large B-cell lymphoma and mantle cell lymphoma research presented at the 2024 ASCO Annual Meeting.
John Burke, MD, discusses some of the most compelling topics in diffuse large B-cell lymphoma and mantle cell lymphoma research presented at the 2024 ASCO Annual Meeting.
John Burke, MD, discusses some...
06/04/2024
Oncology
David Andorsky, MD, Rocky Mountain Cancer Centers
Conference Coverage
06/03/2024

Featuring David Andorsky, MD

Featuring David Andorsky, MD
David Andorsky, MD, discussed results from the phase 2 EPCORE NHL-6 trial, which showed that patients with R/R DLBCL and FL who were treated with subcutaneous epcoritamab demonstrated positive results in the outpatient setting.
David Andorsky, MD, discussed results from the phase 2 EPCORE NHL-6 trial, which showed that patients with R/R DLBCL and FL who were treated with subcutaneous epcoritamab demonstrated positive results in the outpatient setting.
David Andorsky, MD, discussed...
06/03/2024
Oncology
Lorenzo Falchi, MD
Videos
06/19/2023
Lorenzo Falchi, MD presents updated EPCORE NHL-2 data on epcoritamab combined with R-CHOP for the treatment of patients with high-risk diffuse large B-cell lymphoma.
Lorenzo Falchi, MD presents updated EPCORE NHL-2 data on epcoritamab combined with R-CHOP for the treatment of patients with high-risk diffuse large B-cell lymphoma.
Lorenzo Falchi, MD presents...
06/19/2023
Oncology
Lorenzo Falchi, MD
Videos
06/13/2023
Lorenzo Falchi, MD presents extended follow-up from a pivotal phase 2 study on CD20-CD3 bispecific antibody glofitamab monotherapy for patients with R/R DLBCL.
Lorenzo Falchi, MD presents extended follow-up from a pivotal phase 2 study on CD20-CD3 bispecific antibody glofitamab monotherapy for patients with R/R DLBCL.
Lorenzo Falchi, MD presents...
06/13/2023
Oncology
Nirav Niranjan Shah, MD
Videos
06/07/2023
At the 2023 American Society of Clinical Oncology Annual Meeting, Nirav Niranjan Shah, MD, shared findings from a phase 2 trial of split-dose R-CHOP for older patients with DLBCL.
At the 2023 American Society of Clinical Oncology Annual Meeting, Nirav Niranjan Shah, MD, shared findings from a phase 2 trial of split-dose R-CHOP for older patients with DLBCL.
At the 2023 American Society of...
06/07/2023
Oncology
Conference Coverage
06/02/2023

Jordan Kadish

Jordan Kadish
Findings from a phase 3 trial indicated that a polatuzumab vedotin and R-CHP regimen significantly improved the progression-free survival among elderly patients with diffuse large B-cell lymphoma compared to an R-CHOP regimen.
Findings from a phase 3 trial indicated that a polatuzumab vedotin and R-CHP regimen significantly improved the progression-free survival among elderly patients with diffuse large B-cell lymphoma compared to an R-CHOP regimen.
Findings from a phase 3 trial...
06/02/2023
Oncology
Conference Coverage
06/02/2023

Jordan Kadish

Jordan Kadish
Findings from the phase 2 MOLTO trial indicated that atezolizumab, obinutuzumab, and venetoclax combination treatment yielded durable remissions among patients with untreated DLBCL variant of Richter syndrome.
Findings from the phase 2 MOLTO trial indicated that atezolizumab, obinutuzumab, and venetoclax combination treatment yielded durable remissions among patients with untreated DLBCL variant of Richter syndrome.
Findings from the phase 2 MOLTO...
06/02/2023
Oncology

Advertisement

Advertisement

Advertisement

Advertisement